Leukotrienes in Asthma (Q35129201)

6 August 2017

title

Leukotrienes in asthma (English)

1 reference

6 August 2017

1 reference

1

Jeffrey M Drazen

0 references

Jeffrey M. Drazen

1

object named as

Jeffrey M. Drazen

0 references

language of work or name

English

0 references

publication date

1 January 2003

1 reference

full work available at URL

6 August 2017

2003

0 references

http://link.springer.com/content/pdf/10.1007/978-1-4419-9194-2_1.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Advances in Experimental Medicine and Biology

3 January 2024

published in

1 reference

6 August 2017

volume

525

1 reference

6 August 2017

page(s)

1-5

1 reference

Effects of Intravenous Administration of Slow-Reacting Substance of Anaphylaxis, Histamine, Bradykinin, and Prostaglandin F2α on Pulmonary Mechanics in the Guinea Pig

6 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock

3 January 2024

2

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Leukotriene C: a slow-reacting substance from murine mastocytoma cells

3 January 2024

3

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Antileukotrienes in the treatment of asthma

3 January 2024

4

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Treatment of asthma with drugs modifying the leukotriene pathway.

3 January 2024

5

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases

3 January 2024

6

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Leukotrienes are potent constrictors of human bronchi

3 January 2024

7

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Bronchoconstrictor effects of leukotriene C in humans

3 January 2024

8

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis

3 January 2024

10

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Recovery of Leukotriene E4from the Urine of Patients with Airway Obstruction

3 January 2024

11

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Diurnal variation of urinary leukotriene E4 and histamine excretion rates in normal subjects and patients with mild-to-moderate asthma

3 January 2024

12

96

643

K Asano

1995

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Lung function improvement in asthma with a cysteinylleukotriene receptor antagonist

3 January 2024

13

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma

3 January 2024

14

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

3 January 2024

15

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Heterogeneity of therapeutic responses in asthma

3 January 2024

16

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Evaluation of the diurnal variation in the pharmacokinetics of zileuton in healthy volunteers

3 January 2024

17

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment

3 January 2024

18

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma

3 January 2024

20

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group

3 January 2024

21

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Effect of pranlukast, a leukotriene receptor antagonist, in patients with severe asthma refractory to corticosteroids

3 January 2024

22

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids

3 January 2024

23

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial

3 January 2024

24

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Effects of a PAF-antagonist (BN 52063) on bronchoconstriction and platelet activation during exercise induced asthma

3 January 2024

26

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response

3 January 2024

27

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

3 January 2024

28

1 reference

https://api.crossref.org/works/10.1007/978-1-4419-9194-2_1

3 January 2024

Identifiers

0 references

1 reference